TITLE: Plasma Vaporization of the Prostate for Treatment of Benign Prostatic Hypertrophy: A Review of Clinical and Cost-Effectiveness, and Safety
|
|
- Melvyn Horace Shelton
- 5 years ago
- Views:
Transcription
1 TITLE: Plasma Vaporization of the Prostate for Treatment of Benign Prostatic Hypertrophy: A Review of Clinical and Cost-Effectiveness, and Safety DATE: 05 March 2014 CONTEXT AND POLICY ISSUES Benign prostatic hyperplasia (BPH), a nonmalignant enlargement of the prostate gland commonly occurring in men after the age of 50 and sometimes leading to compression of the urethra and obstruction of the flow of urine, occurs in about 25% of men over the age of 50 years in Canada. 1 There are various treatment options for BPH, from watchful waiting, to drug therapies, to phytotherapy, to minimally invasive therapies. 2 Minimally invasive therapy includes techniques such as transurethral resection of the prostate (monopolar or standard TURP), transurethral vaporization of the prostate (TUVP), laser therapies, transurethral microwave thermotherapy (TUMT), high intensity focused ultrasound (HIFU), transurethral needle ablation (TUNA), photoselective vaporization of the prostate (Greenlight Laser), prostatic stents, intraprostatic ethanol injections, and botulinum toxin A injections. 3 The introduction of bipolar technology has led to better outcomes than with monopolar technology, with techniques such as bipolar transurethral resection in saline (TURis or bipolar TURP) and, most recently, bipolar plasma vaporization of the prostate (BPVP). In BPVP, vaporization of the irrigation fluid causes a thin layer of gas (called plasma) to form around the electrode that will remove the upper layers of prostatic tissue without subjecting surrounding tissue to thermal load. 4,5 Recently, to prevent generator overheating problems that standard BPVP (S-BPVP, Olympus PlasmaButton, Olympus, MA, USA) may cause, continuous BPVP techniques (C-BPVP, Olympus Europe, Hamburg, Germany) have been developed with the use of a second generation energy source to produce a continuous plasma activation phenomenon. 4,6 This review aims to review the clinical efficacy, safety and cost-effectiveness of BPVP for the treatment of BPH as compared to TURP. Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report. Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. This report may be used for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners own terms and conditions.
2 RESEARCH QUESTIONS 1. What is the evidence for the clinical efficacy and safety of plasma vaporization of the prostate compared with transurethral resection of the prostate, for patients with benign prostatic hypertrophy? 2. What is the evidence for the cost-effectiveness of plasma vaporization of the prostate compared with transurethral resection of the prostate, for patients with benign prostatic hypertrophy? KEY FINDINGS Findings from six RCTs and one retrospective study support BPVP as a reliable alternative to TURP, with better efficacy outcomes and similar complication rates in short and medium term follow-up periods. For follow-up period up to 100 months, limited evidence showed that BPVP reduced BPH symptoms and reoperation rates compared to TURP. There was no evidence found on the cost-effectiveness of BPVP compared to TURP, for patients with BPH. METHODS Literature Search Strategy A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 2), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2009 and February 4, Internet links were provided, where available. Selection Criteria and Methods One reviewer screened citations and selected studies. In the first level of screening, titles and abstracts were reviewed for relevance. Full texts of any relevant titles or abstracts were retrieved, and assessed for inclusion. The final article selection was based on the inclusion criteria presented in Table 1. Table 1: Selection Criteria Population Adult patients with BPH Intervention Comparator Outcomes Study Designs Plasma vaporization of the prostate (may also be referred to as BPVP or plasma kinetic vaporization) TURP Clinical benefits, safety and harm, improved patient outcomes Cost effectiveness Health technology assessments (HTA), systematic reviews (SRs), meta-analyses (MAs), randomized controlled trials (RCTs), non- RCTs, and economic evaluations. Plasma vaporization for BHP 2
3 Exclusion Criteria Articles were excluded if they did not meet the selection criteria in Table 1, if they were published prior to January 2009, if they were duplicate publications of the same study, or if they were referenced in a selected systematic review. Critical Appraisal of Individual Studies The quality of the included trials was assessed using the Downs and Black checklist. 7 Numeric scores were not calculated. Instead, the strengths and limitations of the study are summarized and presented. SUMMARY OF EVIDENCE Quantity of Research Available The literature search yielded 97 citations. After screening of abstracts from the literature search and from other sources, 15 potentially relevant studies were selected for full-text review. Seven studies met the inclusion criteria and were included in the review. The PRISMA flowchart in Appendix 1 details the process of the study selection. Summary of Study Characteristics A detailed summary of the included study is provided in Appendix 2. Study design Six RCTs 8-13 and one retrospective study 14 were included in the report. Outcomes were measured at 1, 3, 6 months, 8,9,13,14 at 1, 3, and 12 months, 12 at 1,3, 6, 12, and 18 months, 10 or at 60, 100 months. 11 Five studies were conducted in Europe, 8,10-13 and two in Asia. 9,14 Population The included studies enrolled men with BPH and moderate to severe lower urinary tract symptoms, with an overall age range of 51 to 85 years old. Interventions and comparators Interventions were C-BPVP, 8 or S-BPVP Comparators were S-BPVP and monopolar TURP, 8 monopolar TURP, 9,11-13 or monopolar TURP and bipolar TURP. 10,14 Outcomes The most frequent reported efficacy outcomes were operation time, catheterization time, hospital stay, Qmax (maximum flow rate), PVR or PVUR (post-void residual urine volume), PSA (prostate specific antigen) level, IPSS (international prostate symptom score), and HRQL (health-related quality of life). Safety/complication outcomes such as re-catheterization, bladder neck sclerosis, capsular perforation rate, blood loss, hemoglobin level, post-operative hematuria, and clot retention were also reported. Plasma vaporization for BHP 3
4 Summary of Critical Appraisal Six of the included trials were randomized controlled trials and one study was a retrospective study. 14 All included studies had hypotheses, method of population selection, main outcomes, interventions, patient characteristics, and main findings clearly described. The findings from each study were generalizable to the patients with the condition in the context of European and Asian health care systems where the trials were conducted. It is unclear in all included studies whether patients were blinded of the procedure. The team in charge of post-operative care and follow-up was unaware of the treatment method in three trials. 8,10,13 Losses to follow-up were described in one study. 12 Five studies did not indicate whether the study had sufficient power to detect a clinically important effect. 9,11-14 One study indicated that the first author received honoraria from the manufacturer at company sponsored symposia, 8 four studies mentioned there was no conflict of interest declared by the authors, and two studies did not report conflict of interest. 9,10 Details of the strengths and limitations of the included studies are summarized in Appendix 3. Summary of Findings Main findings of included studies are summarized in detail in Appendix What is the evidence for the clinical efficacy and safety of plasma vaporization of the prostate compared with transurethral resection of the prostate, for patients with benign prostatic hypertrophy? Six RCTs 8-13 and one retrospective study 14 compared the clinical effectiveness and safety of BPVP to TURP, for patients with BPH. In general, BPVP represents a reliable alternative to TURP, with better efficacy outcomes and similar complication rates in short and medium term follow-up periods. For long term follow-up periods, limited evidence showed that BPVP reduced BPH symptoms and reoperation rates compared to TURP. One controlled trial randomized 180 men with BPH to C-BPVP, S-BPVP or monopolar TURP (i.e., standard TURP) and followed-up at 1,3 and 6 months post operatively. 8 Findings showed that C-BPVP performed better than S-BPVP, and that both C-BPVP and S-BPVP provided statistically better efficacy (e.g, operation time, catheterization time, hospital stay, IPSS and Qmax), and safety outcomes (e.g., hemoglobin level decrease, capsular perforation rate, postoperative hematuria rate) at 1,3 and 6 months follow-up compared with TURP. There was no statistically significant difference in HRQL, PVR, PSA levels and prostate volumes in three study arms. Five RCTs which included a total of 852 men with BPH, compared S-BPVP to monopolar TURP 9,11-13 or to monopolar TURP and bipolar TURP. 10 Short and medium term efficacy, safety outcomes and HRQL were assessed at 1, 3, 6 months, 9,13 at 1, 3, and 12 months, 12 at 1,3, 6, 12, and 18 months, 10 and longer term outcomes were assessed at 60, and 100 months. 11 Among trials with short and medium term follow-up, one trial reported no statistical difference in IPSS, PVR, Qmax and prostate volumes between the S-BPVP and monopolar TURP groups up to 12 months follow-up. 12 the remaining trials found better efficacy (e.g., operation time, catheterization time, hospital stay, IPSS, Qmax) and safety outcomes (e.g., blood loss, hemoglobin level decrease, capsular perforation rate, post-operative hematuria rate, bladder neck sclerosis, clot retention rate) in patients with S-BPVP compared to monopolar TURP, 9,13 or Plasma vaporization for BHP 4
5 compared to monopolar and bipolar TURP. 10 HRQL which was measured in one trial, and no statistical difference was observed between S-BPVP and monopolar TURP up to 6 months post-surgery. 13 For the trial with long term follow-up, 11 S-BPVP statistically improved IPSS compared with monopolar TURP but no statistical difference between the two techniques was found for Qmax at 60 months and at 100 months follow-up. Reoperation due to persistent obstructive symptoms was performed in six patients in the S-BPVP group and four patients in the monopolar TURP group at 100 months follow-up. One observational study retrospectively analyzed 73 men with BPH who underwent S-BPVP, monopolar TURP, or bipolar TURP. 14 There was no statistical difference in operative time in the three groups. S-BPVP lead to a statistically significant improvement in efficacy outcomes (e.g., procedural irrigation fluid volume, postoperative irrigation duration, catheter duration, and hospital stay) compared with monopolar TURP and bipolar TURP. The S-BPVP group had no complications; three transfusions and four clot retentions occurred in the monopolar TURP group; one transfusion and one clot retention occurred in the bipolar TURP group. 2. What is the evidence for the cost-effectiveness of plasma vaporization of the prostate compared with transurethral resection of the prostate, for patients with benign prostatic hypertrophy? There was no evidence found on the cost-effectiveness of BPVP compared with TURP for patients with BPH. Limitations The main limitation of the included studies was the limited sample size (five out of six studies had a sample size < 200 patients) and short term follow-up (only one study had follow up > 18 months). Additionally, the clinical significance of potentially small but statistically significant difference in some outcomes is unclear. Only one study examined the comparative effect of B- BPVP. Most studies compared S-BPVP to monopolar (i.e., standard) TURP, with limited evidence on the comparison to bipolar TURP. Findings are therefore mainly based on the comparison between S-BPVP to monopolar TURP while bipolar technologies are emerging. Because all included studies were conducted in Europe or Asia, generalizability of the findings to a Canadian context is limited. There is no evidence found on the cost-effectiveness of BPVP compared with TURP for patients with BPH. CONCLUSIONS AND IMPLICATIONS FOR DECISION OR POLICY MAKING Findings from six RCTs and one retrospective study support BPVP as a reliable alternative to TURP, with better efficacy outcomes and similar complication rates in short and medium term follow-up periods. For longer follow-up periods, limited evidence showed that BPVP reduced BPH symptoms and reoperation rates compared to TURP. The comparative findings between BPVP and TURP from this review need to be interpreted with caution, partly because of the recent advances in bipolar technology. Bipolar TURP can potentially offer advantages over monopolar (or standard) TURP. Meta-analyses have shown that bipolar and standard TURP may have similar short term efficacy but bipolar TURP may lead to a better safety profile. 15,16 Similarly, limited evidence suggested B-BPVP offered shorter operative time than S-BPVP. 8 Decision makers may need to balance the potential benefits and costs of bipolar technology Plasma vaporization for BHP 5
6 compared with monopolar or standard technology. There was no evidence found on the costeffectiveness of BPVP compared with TURP for patients with BPH. PREPARED BY: Canadian Agency for Drugs and Technologies in Health Tel: Plasma vaporization for BHP 6
7 REFERENCES 1. Menon D. Photoselective vaporization of the prostate (PVP) for the treatment of benign prostatic hyperplasia (BPH) [Internet]. Edmonton: University of Alberta; 2007 May. (Alberta Health Technologies Decision Process). [cited 2014 Mar 5]. Available from: 2. Shrivastava A, Gupta VB. Various treatment options for benign prostatic hyperplasia: a current update. J Midlife Health [Internet] Jan [cited 2014 Feb 6];3(1):10-9. Available from: 3. Van Hest P, D'Ancona F. Update in minimal invasive therapy in benign prostatic hyperplasia. Minerva Urol Nefrol Sep;61(3): Olympus [Internet]. TURis plasma vaporisation. The innovative BPH treatment - plasma vaporisation of the prostate; 2014 [cited 2014 Feb 19]. Available from: zation/plasma_vaporization.html 5. McClelland M. Olympus PlasmaButton transurethral vaporization technique for benign prostatic hyperplasia. Can J Urol [Internet] Apr [cited 2014 Feb 6];18(2): Available from: 6. Geavlete B, Jecu M, Geavlete P. Continuous plasma vaporisation: a new step forward in BPH endoscopic treatment. Eur Urol Today. 2012;24(3): Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health [Internet] Jun [cited 2014 Feb 11];52(6): Available from: 8. Geavlete B, Stanescu F, Moldoveanu C, Geavlete P. Continuous vs conventional bipolar plasma vaporisation of the prostate and standard monopolar resection: a prospective, randomised comparison of a new technological advance. BJU Int Jun Zhang SY, Hu H, Zhang XP, Wang D, Xu KX, Na YQ, et al. Efficacy and safety of bipolar plasma vaporization of the prostate with "button-type" electrode compared with transurethral resection of prostate for benign prostatic hyperplasia. Chin Med J (Engl) Nov;125(21): Geavlete B, Georgescu D, Multescu R, Stanescu F, Jecu M, Geavlete P. Bipolar plasma vaporization vs monopolar and bipolar TURP-A prospective, randomized, long-term comparison. Urology Oct;78(4): Muslumanoglu AY, Yuruk E, Binbay M, Akman T. Transurethral resection of prostate with plasmakinetic energy: 100 months results of a prospective randomized trial. BJU Int Aug;110(4): Plasma vaporization for BHP 7
8 12. Nuhoglu B, Balci MB, Aydin M, Hazar I, Onuk O, Tas T, et al. The role of bipolar transurethral vaporization in the management of benign prostatic hyperplasia. Urol Int. 2011;87(4): Geavlete B, Multescu R, Dragutescu M, Jecu M, Georgescu D, Geavlete P. Transurethral resection (TUR) in saline plasma vaporization of the prostate vs standard TUR of the prostate: 'the better choice' in benign prostatic hyperplasia? BJU Int Dec;106(11): Lee YT, Ryu YW, Lee DM, Park SW, Yum SH, Han JH. Comparative Analysis of the Efficacy and Safety of Conventional Transurethral Resection of the Prostate, Transurethral Resection of the Prostate in Saline (TURIS), and TURIS-Plasma Vaporization for the Treatment of Benign Prostatic Hyperplasia: A Pilot Study. Korean J Urol [Internet] Nov [cited 2014 Feb 6];52(11): Available from: Mamoulakis C, Ubbink DT, de la Rosette JJ. Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. Eur Urol Nov;56(5): Burke N, Whelan JP, Goeree L, Hopkins RB, Campbell K, Goeree R, et al. Systematic review and meta-analysis of transurethral resection of the prostate versus minimally invasive procedures for the treatment of benign prostatic obstruction. Urology May;75(5): Plasma vaporization for BHP 8
9 Appendix 1: Selection of Included Studies 97 citations identified from electronic literature search and screened 84 citations excluded 13 potentially relevant articles retrieved for scrutiny (full text, if available) 2 relevant reports retrieved from other sources (grey literature, hand search) 15 potentially relevant reports 8 reports excluded (irrelevant designs, population, interventions or outcomes) 7 reports included in review Plasma vaporization for BHP 9
10 Appendix 2: Characteristics of Included Studies Table A1: Characteristics of Included studies First Author, Year, Country Sample Size, Patient Characteristics, Length of Followup Conflict of interest Randomized controlled trials Geavlete, , Romania Zhang, , China Geavlete, , Romania 180 men with BPH, equally randomized to C-BPVP, S- BPVP or monopolar TURP Follow up at 1, 3 and 6 months after surgery First author received honoraria from Olympus at company sponsored symposia 30 men with BPH, equally randomized to BPVP or monopolar TURP Follow up at 1, 3 and 6 months after surgery Conflict of interest not stated 510 men with BPH, equally randomized to S-BPVP, monopolar TURP, or bipolar TURP (TURis) Follow-up at 1,3,6,12, and 18 months after surgery Intervention Comparator(s) Main Study Outcomes C-BPVP S-BPVP, monopolar TURP Operation time Hemoglobin level Capsular perforation rate Post-operative hematuria rate Catheterization time Hospital stay Q max (maximum flow rate) Post-void residual urine volume Prostate volume PSA level IPSS Health-related quality of life S-BPVP Monopolar TURP Operation time Blood loss Hemoglobin level Na level Catheterization time Prostate volume Hospital stay Q max IPSS S-BPVP Monopolar TURP Bipolar TURP (TURis) Operation time Hemoglobin level Capsular perforation rate Post-operative hematuria rate Catheterization time Hospital stay Q max IPSS Muslumanoglu, , Turkey Conflict of interest not stated 67 men with BPH, randomized to S- BPVP (PlasmaKinetic) (n = 34)or monopolar TURP (n = 33) Follow-up at 60 and 100 months S-BPVP Monopolar TURP Operation time Catheterization time Post-operative complications Qmax IPSS Reoperation rate Plasma vaporization for BHP 10
11 Table A1: Characteristics of Included studies First Author, Year, Country Sample Size, Patient Characteristics, Length of Followup Conflict of interest Intervention Comparator(s) Main Study Outcomes Nuhoglu, , Turkey No conflict of interest declared by authors 90 men with BPH, equally randomized to S-BPVP or monopolar TURP Follow-up at 1, 3, and 12 months S-BPVP Monopolar TURP Q max (maximum flow rate) Post-void residual urine volume Prostate volume IPSS Geavlete, , Romania Observational studies Lee, , Korea No conflict of interest declared by authors 155 men with BPH, randomized to S- BPVP, or monopolar TURP Follow-up at 1,3, and 6 months No conflict of interest declared by authors 73 consecutive men with BPH who underwent monopolar TURP, bipolar TURP(TURis), or S- BPVP were retrospectively analyzed. Follow-up at 1, 3, and 6 months No conflict of interest declared by authors S-BPVP Monopolar TURP Operation time Hemoglobin level Capsular perforation rate Post-operative hematuria rate Catheterization time Hospital stay Q max (maximum flow rate) Post-void residual urine volume Prostate volume PSA level IPSS Health-related quality of life S-BPVP Monopolar TURP Bipolar TURP (TURis) Operation time Hemoglobin level Transfusion rate Catheterization time Hospital stay Q max (maximum flow rate) Post-void residual urine volume Prostate volume PSA level IPSS HRQL: health-related quality of life BPH: benign prostatic hypertrophy; C-BPVP: continuous bipolar plasma vaporization of the prostate; HRQL: healthrelated quality of life; IPSS: international prostate symptom score; PSA: prostate specific antigen; PVP: plasma vaporization of the prostate; S-BPVP: standard bipolar plasma vaporization of the prostate; TURP: transurethral resection of the prostate. Plasma vaporization for BHP 11
12 Appendix 3: Summary of Critical Appraisal of Included Study Table A2: Summary of Critical Appraisal of Included Studies (Downs and Black 7 ) First Author, Strengths Limitations Publication Year Geavlete, hypothesis clearly described patients randomized method of selection from source population and representation described main outcomes, interventions, patient characteristics, and main findings clearly described estimates of random variability and actual probability values provided study had sufficient power to detect a clinically important effect Zhang, hypothesis clearly described patients randomized method of selection from source population and representation described main outcomes, interventions, patient characteristics, and main findings clearly described estimates of random variability and actual probability values provided Geavlete, hypothesis clearly described patients randomized method of selection from source population and representation described main outcomes, interventions, patient characteristics, and main findings clearly described estimates of random variability and actual probability values provided study had sufficient power to detect a clinically important effect Muslumanoglu, hypothesis clearly described patients randomized method of selection from source population and representation described main outcomes, interventions, patient characteristics, and main findings clearly described estimates of random variability and actual probability values provided Nuhoglu, hypothesis clearly described patients randomized method of selection from source population and representation described losses to follow-up described main outcomes, interventions, patient characteristics, and main findings clearly described unclear whether patients were blinded losses to follow-up not described unclear whether patients were blinded losses to follow-up not described unclear whether study had sufficient power to detect a clinically important effect unclear whether patients were blinded losses to follow-up not described unclear whether patients were blinded losses to follow-up not described unclear whether study had sufficient power to detect a clinically important effect unclear whether patients were blinded unclear whether study had sufficient power to detect a clinically important effect Plasma vaporization for BHP 12
13 Table A2: Summary of Critical Appraisal of Included Studies (Downs and Black 7 ) First Author, Strengths Limitations Publication Year estimates of random variability and actual probability values provided Geavlete, hypothesis clearly described patients randomized method of selection from source population and representation described main outcomes, interventions, patient characteristics, and main findings clearly described estimates of random variability and actual probability values provided Lee, hypothesis clearly described patients not randomized method of selection from source population and representation described main outcomes, interventions, patient characteristics, and main findings clearly described estimates of random variability and actual probability values provided unclear whether patients were blinded losses to follow-up not described unclear whether study had sufficient power to detect a clinically important effect patients not blinded losses to follow-up not described unclear whether study had sufficient power to detect a clinically important effect Plasma vaporization for BHP 13
14 Appendix 4: Main Study Findings and Authors Conclusions Table A3: Main Study Findings and Authors Conclusions First Author, Publication Year Main Study Findings Authors Conclusions Research question 1 (evidence for the clinical efficacy and safety of plasma vaporization of the prostate compared with transurethral resection of the prostate, for patients with benign prostatic hypertrophy) Geavlete, Operation time: statistically significantly shorter for C-BPVP (31.5 min) than for S-BPVP (40.6 min) and monopolar TURP (49.8 min), with a 22.4% and 39.1% decrease in duration for C-BPVP when compared with S-BPVP and TURP, respectively (P < 0.001). For C-BPVP and S-BPVP compared with TURP, hemoglobin level decrease (0.4 and 0.6 vs 1.4 g/dl), capsular perforation rate (1.7% and 3.3% vs 10%), postoperative hematuria rate (1.7% and 1.7% vs 13.3%), catheterisation period (24.1 and 23.9 vs hours), and hospital stay (2.1 and 2.2 vs. 4.5 days) were statistically significantly lower. (P < 0.001) IPSS: at 1, 3 and 6 months follow-up, statistically ameliorated for C-BPVP and S-BPVP compared with TURP (P < 0.001) Qmax: at 1, 3 and 6 months follow-up, statistically ameliorated for C-BPVP and S-BPVP compared with TURP (P < 0.05) The operation time for C-BPVP was on average 20% and 40% quicker than S-BPVP and TURP, respectively. Both C-BPVP and S-BPVP had better perioperative safety and improved follow-up voiding and symptom scores than TURP (p 288) Zhang, Geavlete, Similar HRQL scores, PVRs, PSA levels and postoperative prostate volumes in all three study arms. BPVP statistically significantly superior to TURP in terms of: indwelling catheter time (4.1 vs. 6.8 days, P=0.000), blood loss (64.7 vs ml, P=0.040), hospital stay (8.7 vs days, P=0.000), IPSS (4.2 vs. 9.3, P=0.049), QOL (P=0.027), Qmax (P=0.038), hemoglobin (130.7 vs , g/l, P=0.047), Na+ level (P=0.046) and operation time (39.0 vs min, P=0.004). Capsular perforation rate (1.2% vs. 7.1% vs. 9.4%), intraoperative bleeding rate (1.8% vs. 8.2% vs. 13.5%), mean hemoglobin drop (0.5 g/dl vs. 1.2 g/dl vs. 1.6 g/dl): statistically significantly decreased for BPVP compared to bipolar or monopolar TURP. (P = 0.004) Postoperative hematuria (2.9% vs. 4.7% vs. 15.3%), blood transfusion (1.2% vs. 1.8% vs. 6.5%), and clot retention rates (0.6% vs. 1.2% vs. 4.1%): statistically significantly lower in the BPVP and bipolar TURP groups compared to the monopolar TURP group. (P = ) Operation time: shorter for BPVP patients(39.7 min) compared to monopolar (55.6 min) and bipolar TURP (52.1 min) groups (P = ) Catheterization period significantly reduced for BPVP (23.5 h), followed by bipolar TURP (46.3 h) compared with monopolar TURP (72.8 h). (P = ) Hospital stay significantly reduced for BPVP (1.9 days), followed by bipolar TURP (3.1 days) compared with monopolar TURP (4.2 days). (P = ) Compared with TURP, BPVP with button-type electrode shows superior efficacy and safety. Therefore, BPVP with button-type electrode represents a valuable endoscopic treatment alternative for BPH patients (p 3811) BPVP represents a valuable endoscopic treatment alternative for BPH patients, with superior efficacy and satisfactory complication rate. The long-term follow-up emphasized durable improvements of the postoperative parameters for BPVP (p 930) Plasma vaporization for BHP 14
15 Table A3: Main Study Findings and Authors Conclusions First Author, Publication Year Main Study Findings Authors Conclusions Muslumanoglu, Nuhoglu, Geavlete, Lee, Irritative symptoms and urethral strictures rates: similar in the 3 series. Re-catheterization, bladder neck sclerosis, and retreatment rates: significantly lower in the BPVP group. (P < 0.05) IPSS, Qmax: at 1, 3, 6, 12, and 18 months follow-up, BPVP showed significantly superior parameters compared to monopolar or bipolar TURP. (P = ) Operation time: shorter in the Plasmakinetics group (40.3 min) than in the TURP group (57.8 min, P <0.001) Catheterization time: shorter in the Plasmakinetics group (2.3 days) than in the TURP group (3.58 days, P = 0.001) IPSS at 60 months: increased to 8.5 ± 1.6 in the Plasmakinetic group and 7.9 ± 1.3 in the TURP group (P = 0.045) IPSS at 100 months: increased to 9.4 ± 0.9 in the Plasmakinetic group (P = 0.045) and 8.7± 1.2 in the TURP group (P = 0.017) Qmax at 60 months and at 100 months: changes from baseline not statistically significant (P = 0.31) Reoperation: performed in six patients in the Plasmakinetic group and four patients in the TURP group at 100 months follow-up IPSS, PVRU, Qmax, and prostatic volumes: no significant differences between the two groups at 1, 3, and 12 months follow-up Postoperative catheter indwelling times (54.3 vs hours) and Na+ serum concentrations: significantly lower in TUVP group than TURP group (P < 0.005) No statistically significant difference in operation time between the two groups. Operative time (35.1 vs min), catheterization period (23.8 vs hours) and hospital stay (47.6 vs hours): statistically significantly shorter for TURis-PVP (S-BPVP) patients compared to monopolar TURP (P < 0.05) IPSS: statistically significantly better for TURis-PVP group (S- BPVP) compared to monopolar TURP at 1, 3 and 6 months follow-up (P < 0.05) Operation time: no statistically significant differences between the 3 groups (P = 0.211). Procedural irrigation fluid volume, postoperative irrigation duration, catheter duration (2.80 vs vs days), and hospital stay (4.86 vs vs days): statistically Our 100 months results suggest that Plasmakinetic technology can be used as a first-line treatment instead of monopolar TURP. (p 546) We detected similar effectiveness and morbidity rates in both groups. Bipolar TUVP has advantages such as shorter catheter indwelling times and hospital stays, and fewer bleeding episodes without any risk of transurethral resection syndrome. We believe that TUVP might be an alternative to TURP which is currently the gold standard treatment in BPH. (p 400) TURis-PVP represents a valuable endoscopic treatment alternative for patients with BPE, with superior efficacy, short-term results and complication rates compared with monopolar TURP. (p 1695) TURIS and TURIS-V were effective for the surgical treatment of BPH in addition to conventional TUR-P.TURIS-V was not inferior to conventional TUR-P or TURIS in terms of safety. (p 763) Plasma vaporization for BHP 15
16 Table A3: Main Study Findings and Authors Conclusions First Author, Publication Year Main Study Findings significantly less for TURIS-V (S-BPVP) compared with conventional TUR-P (monopolar TURP) and TURIS (bipolar TURP) (P < 0.05) Authors Conclusions IPSS, HRQL, Qmax, PVR: improved compared to baseline for all techniques (no figures on comparison between techniques) Hemoglobin levels: no statistically significant differences between the groups before and after the operations. (P > 0.05) Transfusions and clot retentions: 3 transfusions and 4 clot retentions in the TUR-P group (monopolar TURP); 1 transfusion and 1 clot retention in the TURIS group (bipolar TURP). The TURIS-V group (S-BPVP) had no complications. Research question 2 (evidence for the cost-effectiveness of plasma vaporization of the prostate compared with transurethral resection of the prostate, for patients with benign prostatic hypertrophy) No evidence found on the cost-effectiveness of plasma vaporization of the prostate compared with transurethral resection of the prostate, for patients with benign prostatic hypertrophy BPH: benign prostatic hypertrophy; C-BPVP: continuous bipolar plasma vaporization of the prostate; HRQL: healthrelated quality of life; IPSS: international prostate symptom score; PVR or PVRU: post-void residual urine volume; PSA: prostate specific antigen; PVP: plasma vaporization of the prostate; Qmax: maximum flow rate; S-BPVP: standard bipolar plasma vaporization of the prostate; TURP: transurethral resection of the prostate; TUVP: transurethral vaporization of the prostate Plasma vaporization for BHP 16
Service Line: Rapid Response Service Version: 1.0 Publication Date: March 01, 2017 Report Length: 16 Pages
CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Bipolar versus Monopolar Transurethral Resection of the Prostate or GreenLight Laser Treatment: A Review of Clinical and Cost-Effectiveness
More informationTITLE: Montelukast for Sleep Apnea: A Review of the Clinical Effectiveness, Cost Effectiveness, and Guidelines
TITLE: Montelukast for Sleep Apnea: A Review of the Clinical Effectiveness, Cost Effectiveness, and Guidelines DATE: 17 January 2014 CONTEXT AND POLICY ISSUES Obstructive sleep apnea (OSA) is a common
More informationTITLE: Hyperbaric Oxygen Therapy for Adults with Mental Illness: A Review of the Clinical Effectiveness
TITLE: Hyperbaric Oxygen Therapy for Adults with Mental Illness: A Review of the Clinical Effectiveness DATE: 27 August 2014 CONTEXT AND POLICY ISSUES Mental illness, including major depressive episode,
More informationTITLE: Patient-Controlled Analgesia for Acute Injury Transfers: A Review of the Clinical Effectiveness, Safety, and Guidelines
TITLE: Patient-Controlled Analgesia for Acute Injury Transfers: A Review of the Clinical Effectiveness, Safety, and Guidelines DATE: 11 August 2014 CONTEXT AND POLICY ISSUES Patient-controlled analgesia
More informationDATE: 04 April 2012 CONTEXT AND POLICY ISSUES
TITLE: Procedure Site Bleeding Complications Following Percutaneous Coronary Interventions or Angioplasty: A Review of Clinical Evidence and Guidelines DATE: 04 April 2012 CONTEXT AND POLICY ISSUES Percutaneous
More informationTITLE: Immediate Osseointegrated Implants for Cancer Patients: A Review of Clinical and Cost-Effectiveness
TITLE: Immediate Osseointegrated Implants for Cancer Patients: A Review of Clinical and Cost-Effectiveness DATE: 13 January 2015 CONTEXT AND POLICY ISSUES According to the World health Organization, the
More informationDATE: 17 July 2012 CONTEXT AND POLICY ISSUES
TITLE: Sterile Pre-filled Saline Syringes for Acute Care Patients: A Review of Clinical Evidence, Cost-effectiveness, Evidence-based Guidelines, and Safety DATE: 17 July 2012 CONTEXT AND POLICY ISSUES
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablative therapies, transurethral needle ablation, Adverse events, sexual side effects of BPH Aging, and incidence of BPH associated with
More informationTITLE: Delivery of Electroconvulsive Therapy in Non-Hospital Settings: A Review of the Safety and Guidelines
TITLE: Delivery of Electroconvulsive Therapy in Non-Hospital Settings: A Review of the Safety and Guidelines DATE: 08 May 2014 CONTEXT AND POLICY ISSUES Electroconvulsive therapy (ECT) is a treatment that
More informationTITLE: Discontinuation of Benzodiazepines and Other Sedative-Hypnotic Sleep Medication in Hospitalized Patients: Clinical Evidence and Guidelines
TITLE: Discontinuation of Benzodiazepines and Other Sedative-Hypnotic Sleep Medication in Hospitalized Patients: Clinical Evidence and Guidelines DATE: 25 September 2015 RESEARCH QUESTIONS 1. What is the
More informationTITLE: Shilla and MAGEC Systems for Growing Children with Scoliosis: A Review of the Clinical Benefits and Cost-Effectiveness
TITLE: Shilla and MAGEC Systems for Growing Children with Scoliosis: A Review of the Clinical Benefits and Cost-Effectiveness DATE: 17 January 2013 CONTEXT AND POLICY ISSUES Early-onset scoliosis (EOS)
More informationExecutive Summary. Non-drug local procedures for treatment of benign prostatic hyperplasia 1. IQWiG Reports - Commission No.
IQWiG Reports - Commission No. N04-01 Non-drug local procedures for treatment of benign prostatic hyperplasia 1 Executive Summary 1 Translation of the executive summary of the final report Nichtmedikamentöse
More informationTITLE: Optimal Oxygen Saturation Range for Adults Suffering from Traumatic Brain Injury: A Review of Patient Benefit, Harms, and Guidelines
TITLE: Optimal Oxygen Saturation Range for Adults Suffering from Traumatic Brain Injury: A Review of Patient Benefit, Harms, and Guidelines DATE: 11 April 2014 CONTEXT AND POLICY ISSUES Traumatic brain
More informationBenign prostatic hyperplasia (BPH) is one of the
MISCELLANEOUS Safety and Efficacy of Bipolar Versus Monopolar Transurethral Resection of the Prostate: A Comparative Study Erkan Hirik, 1 Aliseydi Bozkurt, 1 Mehmet Karabakan, 1 * Huseyin Aydemir, 2 Binhan
More informationComparison of outpatient versus inpatient transurethral prostate resection for benign prostatic hyperplasia: Comparative, prospective bi-centre study
original research Comparison of outpatient versus inpatient transurethral prostate resection for benign prostatic hyperplasia: Comparative, prospective bi-centre study Jae Heon Kim, MD; * Jae Young Park,
More informationYong Taec Lee, Young Woo Ryu, Dong Min Lee, Sang Wook Park, Seung Hee Yum, June Hyun Han
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.11.763 Voiding Dysfunction Comparative Analysis of the Efficacy and Safety of Conventional Transurethral Resection of the Prostate, Transurethral
More informationNOTE: This policy is not effective until April 1, Transurethral Water Vapor Thermal Therapy of the Prostate
NOTE: This policy is not effective until April 1, 2019. Medical Policy Manual Surgery, Policy No. 210 Transurethral Water Vapor Thermal Therapy of the Prostate Next Review: December 2019 Last Review: December
More informationTITLE: Periodic Dental Examinations for Oral Health: A Review of Clinical Effectiveness, Cost Effectiveness, and Guidelines
TITLE: Periodic Dental Examinations for Oral Health: A Review of Clinical Effectiveness, Cost Effectiveness, and Guidelines DATE: 21 May 2014 CONTEXT AND POLICY ISSUES While there is no accepted universal
More informationTITLE: Use of Bupropion in Patients with Depression and the Associated Risk of Seizures: Safety
TITLE: Use of Bupropion in Patients with Depression and the Associated Risk of Seizures: Safety DATE: 1 April 2010 CONTEXT AND POLICY ISSUES: The prevalence of epilepsy ranges from 0.5% to 1%, 1,2 and
More informationVoiding Dysfunction. Joon Seok Kwon, Jung Woo Lee 1, Seung Wook Lee, Hong Yong Choi, Hong Sang Moon. DOI: /kju
www.kjurology.org DOI:10.4111/kju.2011.52.4.269 Voiding Dysfunction Comparison of Effectiveness of Monopolar and Bipolar Transurethral Resection of the Prostate and Open Prostatectomy in Large Benign Prostatic
More informationTITLE: Probenecid Dosing When Given with Cefazolin: Guidelines and Clinical Effectiveness
TITLE: Probenecid Dosing When Given with Cefazolin: Guidelines and Clinical Effectiveness DATE: 21 November 2008 RESEARCH QUESTIONS: 1. What is the evidence for the clinical effectiveness of the 1g dose
More informationSafety and efficacy of photoselective vaporization of the prostate using the 180-W GreenLight XPS laser system in patients taking oral anticoagulants
Clinical Report Safety and efficacy of photoselective vaporization of the prostate using the 180-W GreenLight XPS laser system in patients taking oral anticoagulants Journal of International Medical Research
More informationOverview. Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia. Iain McAuley September 15, 2014
Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia Iain McAuley September 15, 2014 Overview Review of the most recent guidelines for ED and BPH ED Guidelines CUA 2006 AUA 2011
More informationOriginal Policy Date
MP 7.01.39 Transurethral Microwave Thermotherapy Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical
More informationRezūm procedure for the Prostate
Rezūm procedure for the Prostate Mr Jas Kalsi Consultant Urological Surgeon This booklet has been provided to help answer the questions you may have with regards to your enlarged prostate and the Rezūm
More informationService Line: Rapid Response Service Version: 1.0 Publication Date: October 30, 2018 Report Length: 7 Pages
CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Topical Silver Nitrate for the Management of Hemostasis: A Review of Clinical Effectiveness, Cost- Effectiveness, and Guidelines Service Line:
More informationTITLE: Crushed Buprenorphine or Buprenorphine-Naloxone for Opioid Dependency: A Review of the Clinical Effectiveness and Guidelines
TITLE: Crushed Buprenorphine or Buprenorphine-Naloxone for Opioid Dependency: A Review of the Clinical Effectiveness and Guidelines DATE: 18 July 2016 CONTEXT AND POLICY ISSUES Opioid dependence is a chronic
More informationControl & confidence. You deserve both. YOUR GUIDE TO THE TREATMENT OF BPH
Control & confidence. You deserve both. YOUR GUIDE TO THE TREATMENT OF BPH The more you know, the better you ll feel. You ve likely had a discussion with your doctor about BPH 1. What follows are some
More informationControl & confidence. You deserve both.
Learn more about BPH and Plasma therapy Control & confidence. You deserve both. YOUR GUIDE TO THE TREATMENT OF BPH Your doctor is always happy to offer all the guidance you need so that you feel completely
More informationThis report will provide a review on the comparative clinical effectiveness and safety between intranasal triamcinolone and beclomethasone.
TITLE: Intranasal Triamcinolone versus Intranasal Beclomethasone for Acute and Chronic Sinus Inflammation: A Review of Comparative Clinical Effectiveness and Safety DATE: 29 January 2013 CONTEXT AND POLICY
More informationGUIDELINES ON NON-NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION
GUIDELINES ON NON-NEUROGENIC MLE LUTS INCLUDING BENIGN PROSTTIC OBSTRUCTION (Text update March 2015) S. Gravas (Chair), T. Bach,. Bachmann, M. Drake, M. Gacci, C. Gratzke, S. Madersbacher, C. Mamoulakis,
More informationTITLE: Acetylsalicylic Acid for Venous Thromboembolism Prophylaxis: A Review of Clinical Evidence, Benefits and Harms
TITLE: Acetylsalicylic Acid for Venous Thromboembolism Prophylaxis: A Review of Clinical Evidence, Benefits and Harms DATE: 23 August 2011 CONTEXT AND POLICY ISSUES: Thromboembolism occurs when a blood
More informationDATE: 21 November 2012 CONTEXT AND POLICY ISSUES
TITLE: Vitamin E Infused Polyethylene Liners, Conventional Polyethylene Liners, and Cross-Linked Polyethylene Liners for Knee Articular Resurfacing in Adults: A Review of Clinical and Cost-Effectiveness
More information1 Department of Urology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China
ORIGINAL ARTICLE Vol. 42 (4): 747-756, July - August, 2016 doi: 10.1590/S1677-5538.IBJU.2015.0225 Bipolar transurethral enucleation and resection of the prostate versus bipolar resection of the prostate
More informationGUIDELINES ON NON-NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION (BPO)
GUIDELINES ON NON-NEUROGENIC MLE LUTS INCLUDING BENIGN PROSTTIC OBSTRUCTION (BPO) (Text update pril 2014) S. Gravas (chair),. Bachmann,. Descazeaud, M. Drake, C. Gratzke, S. Madersbacher, C. Mamoulakis,
More informationTRANSURETHRAL PLASMA VAPORIZATION OF THE PROSTATE Procedure Guide
TRANSURETHRAL PLASMA VAPORIZATION OF THE PROSTATE Procedure Guide 16299 1 PLASMA VAPORIZATION THERAPY PLASMA Vaporization PLASMA vaporization provides a safe, easy-to-use solution for TUR tissue-management
More information50% of men. 90% of men PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS. Want more information? What are the symptoms?
PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS What is Benign Prostatic Hyperplasia (enlarged prostate)? Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate, the gland that
More informationSubject: Temporary Prostatic Stent and Prostatic Urethral Lift
02-54000-21 Original Effective Date: 03/15/05 Reviewed: 09/27/18 Revised: 10/15/18 Subject: Temporary Prostatic Stent and Prostatic Urethral Lift THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION,
More informationTITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations
TITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations DATE: 29 September 2010 CONTEXT AND POLICY ISSUES: Atrial fibrillation (AF) is the irregular, rapid beating of the
More informationManagement of LUTS after TURP and MIT
Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent
More informationTITLE: Closed Catheter Systems for Prevention of Urinary Tract Infections: A Review of the Clinical Effectiveness
TITLE: Closed Catheter Systems for Prevention of Urinary Tract Infections: A Review of the Clinical Effectiveness DATE: 24 November 2008 CONTEXT AND POLICY ISSUES: Urinary tract infections (UTI) are the
More informationCombination of Thulium Laser Incision and Bipolar Resection Offers Higher Resection. Velocity than Bipolar Resection Alone in Large Prostates
Running Head: combination of thulium laser and bipolar in endoscopic prostatectomy-huang et al. Combination of Thulium Laser Incision and Bipolar Resection Offers Higher Resection Velocity than Bipolar
More informationOriginal Article - Lasers in Urology. Min Ho Lee, Hee Jo Yang, Doo Sang Kim, Chang Ho Lee, Youn Soo Jeon
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.11.737 Original Article - Lasers in Urology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.11.737&domain=pdf&date_stamp=2014-11-16
More informationChapter 2: Methodology
Chapter 2: Methodology TABLE OF CONTENTS Introduction... 2 Study Selection and Data Abstraction... 2 Data Synthesis... 8 Guideline Development and Approvals... 9 Conflict of Interest... 10 Copyright 2010
More informationTransurethral Laser Technology: Treatments for BPH
Transurethral Laser Technology: Treatments for BPH Richard Lee, MD Departments of Urology and Public Health The New York Presbyterian Hospital Weill Medical College of Cornell University Background Traditional
More informationThe Enlarged Prostate Symptoms, Diagnosis and Treatment
The Enlarged Prostate Symptoms, Diagnosis and Treatment MAC00031-01 Rev G Financial support for this seminar has been provided by NeoTract, Inc., the manufacturer of the UroLift System. 1 Today s Agenda
More informationPOLICIES AND PROCEDURE MANUAL
POLICIES AND PROCEDURE MANUAL Policy: MP048 Section: Medical Benefit Policy Subject: Surgical and Minimally Invasive Therapies for the Treatment of Benign Prostatic Hypertrophy I. Policy: Surgical and
More informationCan 80 W KTP Laser Vaporization Effectively Relieve the Obstruction in Benign Prostatic Hyperplasia?: A Nonrandomized Trial
pissn: 2287-428 / eissn: 2287-469 World J Mens Health 212 December 3(3): 16-165 http://dx.doi.org/1.5534/wjmh.212.3.3.16 Original Article Can 8 W KTP Laser Vaporization Effectively Relieve the Obstruction
More informationCADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL
CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Day Surgery versus Overnight Stay for Laparoscopic Cholecystectomy and Laparoscopic Hernia Repair: A Review of Comparative Clinical Effectiveness
More informationTitle: Scoop Stretcher for Restriction of Spinal Motion: Clinical Effectiveness
Title: Scoop Stretcher for Restriction of Spinal Motion: Clinical Effectiveness Date: 28 May 2008 Research question: What is the evidence for the clinical effectiveness of a scoop stretcher to restrict
More informationDATE: 26 August 2013 CONTEXT AND POLICY ISSUES
TITLE: Nd:YAG Laser for the Treatment of Patients with Hidradenitis Suppurativa: A Review of the Clinical Effectiveness, Cost-Effectiveness, and Safety DATE: 26 August 2013 CONTEXT AND POLICY ISSUES Hidradenitis
More informationBenign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia (BPH) Definition Prostate gland enlargement is a common condition as men get older. Also called benign prostatic hyperplasia (BPH), prostate gland enlargement can cause bothersome
More informationEUROPEAN UROLOGY 58 (2010)
EUROPEAN UROLOGY 58 (2010) 349 355 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Benign Prostatic Hyperplasia Editorial by Petrisor Geavlete on pp. 356
More informationTITLE: Dose of Electrical Current for Biphasic Defibrillators for Synchronous Cardioversion in Patients with Tachyarrhythmia: Guidelines
TITLE: Dose of Electrical Current for Biphasic Defibrillators for Synchronous Cardioversion in Patients with Tachyarrhythmia: Guidelines DATE: 5 May 2009 RESEARCH QUESTION: What recommendations exist for
More informationRandomized, controlled trial of laser vs. bipolar plasma vaporization treatment of benign prostatic hyperplasia
ORIGINAL RESEARCH Randomized, controlled trial of laser vs. bipolar plasma vaporization treatment of benign prostatic hyperplasia Thomas A.A. Skinner, MSc, MD; Robert J. Leslie, MSc, MD; Stephen S. Steele,
More informationTITLE: Hyperbaric Oxygen Therapy for Autism: A Review of the Clinical and Cost- Effectiveness
TITLE: Hyperbaric Oxygen Therapy for Autism: A Review of the Clinical and Cost- Effectiveness DATE: 19 November 2009 CONTEXT AND POLICY ISSUES: Autism is a pervasive developmental disorder characterized
More informationEarly-Stage Clinical Experiences of Holmium Laser Enucleation of the Prostate (HoLEP)
JRural Med 2007 ; 2 : 93 97 Original article Early-Stage Clinical Experiences of Holmium Laser Enucleation of the Prostate (HoLEP) Shuzo Hamamoto 1,TakehikoOkamura 1,HideyukiKamisawa 1,KentaroMizuno 1,
More informationLasers in Urology. Ju Hyun Park 1, Hwancheol Son 1,2, Jae-Seung Paick 1. DOI: /kju
www.kjurology.org DOI:10.4111/kju.2010.51.2.115 Lasers in Urology Comparative Analysis of the Efficacy and Safety of Photoselective Vaporization of the Prostate for Treatment of Benign Prostatic Hyperplasia
More informationExperience the Innovative Therapy for Benign Prostate Enlargement
Experience the Innovative Therapy for Benign Prostate Enlargement A Guide to Treatment of Benign Prostatic Hyperplasia 1. 2. The Prostate The prostate gland is a part of the male reproductive system. A
More informationYOUR CHOICE FOR BPH Resection, Vaporization, Enucleation Individual PLASMA Treatment
YOUR CHOICE FOR BPH Resection, Vaporization, Enucleation Individual PLASMA Treatment 12345 15143 16129 PLASMA YOUR CHOICE FOR BPH The Safe Choice Comparable Clinical Outcome with Increased Safety Profile*:
More informationEarly outcome of transurethral enucleation and resection of the prostate versus transurethral resection of the prostate
Singapore Med J 2016; 57(12): 676-680 doi: 10.11622/smedj.2016026 Early outcome of transurethral enucleation and resection of the prostate versus transurethral resection of the prostate Sundaram Palaniappan
More informationOUTCOMES OF HoLEP IN THE RETREATMENT SETTING
OUTCOMES OF HoLEP IN THE RETREATMENT SETTING Tracy Marien 1 MD, Mustafa Kadihasanoglu 1 MD, Teerayut Tangpaitoon 1 MD, Nadya York 2 MD, Andrew T. Blackburne 3 MD, Haidar Abdul-Muhsin 4 MD, Michael S. Borofsky
More informationSurgical procedures for benign prostatic hyperplasia: A nationwide survey in Japan
International Journal of Urology (2011) 18, 166 170 doi: 10.1111/j.1442-2042.2010.02687.x Short Communicationiju_2687 166..170 Surgical procedures for benign prostatic hyperplasia: A nationwide survey
More informationLong-term Follow-up of Transurethral Enucleation Resection of the Prostate for Symptomatic Benign Prostatic Hyperplasia
Journal of Surgery 2016; 4(2): 40-44 http://www.sciencepublishinggroup.com/j/js doi: 10.11648/j.js.20160402.18 ISSN: 2330-0914 (Print); ISSN: 2330-0930 (Online) Long-term Follow-up of Transurethral Enucleation
More informationIS IRRIGATION NECESSARY AFTER MONOPOLAR TURP? OUR 11 YEARS EXPERIENCE
IS IRRIGATION NECESSARY AFTER MONOPOLAR TURP? OUR 11 YEARS EXPERIENCE Prasannakumar K, Venkatesh Krishnamoorthy, Maneesh Sinha, Krishna Prasad T, Pradeepa MG Abstract Objective: This study was conducted
More informationTITLE: Naltrexone for the Treatment of Alcohol Dependence in Individuals with Co- Dependencies: A Review of the Clinical Effectiveness
TITLE: Naltrexone for the Treatment of Alcohol Dependence in Individuals with Co- Dependencies: A Review of the Clinical Effectiveness DATE: 08 October 2009 CONTEXT AND POLICY ISSUES: Poly-drug abuse is
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Medical technology guidance SCOPE The UroLift system for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia 1
More informationSubmitted: August 15, Accepted: September 10, Published: October 15, 2018.
Original Article doi: 10.22374/jeleu.v1i2.21 THULIUM LASER ENUCLEATION OF THE PROSTATE (THULEP) AS A TECHNIQUE FOR TREATMENT OF BPH: EVALUATION OF A SIX-YEAR EXPERIENCE AT A SINGLE INSTITUTION Mahmood
More informationDATE: 22 May 2013 CONTEXT AND POLICY ISSUES
TITLE: Intraperitoneal versus Intravenous Chemotherapy for the Treatment of Ovarian Cancer: A Review of the Comparative Clinical Evidence, Safety, Cost- Effectiveness, and Guidelines DATE: 22 May 2013
More informationISPUB.COM. Photoselective Vaporisation of the Prostate - Independent Surgical Experience Following Comprehensive Resident Training in the Technique.
ISPUB.COM The Internet Journal of Urology Volume 9 Number 4 Photoselective Vaporisation of the Prostate - Independent Surgical Experience Following Comprehensive Resident Training in the Technique. R Eapen,
More informationSurgical Treatment of LUTS in Men with BPE
Patient Information English 35 Surgical Treatment of LUTS in Men with BPE The underlined terms are listed in the glossary. You have been diagnosed with benign prostatic enlargement (BPE) and your doctor
More informationMODULE 3: BENIGN PROSTATIC HYPERTROPHY
MODULE 3: BENIGN PROSTATIC HYPERTROPHY KEYWORDS: Prostatic hypertrophy, prostatic hyperplasia, PSA, voiding dysfunction, lower urinary tract symptoms (LUTS) At the end of this clerkship, the medical student
More informationDATE: 10 February 2016 CONTEXT AND POLICY ISSUES
TITLE: Neuromuscular Monitoring for Patients Receiving Continuous Paralytic or Neuromuscular Blocking Agents: A Review of the Clinical Effectiveness and Guidelines DATE: 10 February 2016 CONTEXT AND POLICY
More informationTITLE: Vacuum Boards for Spinal Motion Restriction: Clinical Effectiveness
TITLE: Vacuum Boards for Spinal Motion Restriction: Clinical Effectiveness DATE: 14 October 2008 RESEARCH QUESTION: What are the clinical benefits and harms of using vacuum boards for spinal motion restriction?
More informationLasers in Urology. Sae Woong Choi, Yong Sun Choi, Woong Jin Bae, Su Jin Kim, Hyuk Jin Cho, Sung Hoo Hong, Ji Youl Lee, Tae Kon Hwang, Sae Woong Kim
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.12.824 Lasers in Urology 120 W Greenlight HPS Laser Photoselective Vaporization of the Prostate for Treatment of Benign Prostatic Hyperplasia in
More informationCADTH RAPID RESPONSE REPORT: REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer: Clinical Effectiveness
CADTH RAPID RESPONSE REPORT: REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer: Clinical Effectiveness Service Line: Rapid Response Service Version: 1.0 Publication Date: August
More informationInitial Experience of High Power Diode Laser for Vaporization of Prostate Muhammad Rafiq Zaki, Mujahid Hussain, Tahir Mehmood, Murtaza Hiraj
Original Article Initial Experience of High Power Diode Laser for Vaporization of Prostate Muhammad Rafiq Zaki, Mujahid Hussain, Tahir Mehmood, Murtaza Hiraj Abstract Objectives: Prospective evaluation
More informationProstate Artery Embolization
Prostate Artery Embolization in the office interventional suite Robert J. Kennedy, M.D. Interventional & Vascular Center Melbourne, Florida The speaker has no financial conflicts of interest to disclose.
More informationTITLE: Abuse and Misuse Potential of Dimenhydrinate: A Review of the Clinical Evidence
TITLE: Abuse and Misuse Potential of Dimenhydrinate: A Review of the Clinical Evidence DATE: 01 December 2015 CONTEXT AND POLICY ISSUES Dimenhydrinate (marketed as Gravol in Canada and Dramamine in the
More informationPROSTATIC EMBOLIZATION FOR BENIGN HYPERPLASIA
St. Louis Hospital PROSTATIC EMBOLIZATION FOR BENIGN HYPERPLASIA INITIAL CLINICAL RESULTS Faculty of Medical Sciences New University of Lisbon JOÃO PISCO LUÍS CAMPOS PINHEIRO TIAGO BILHIM HUGO RIO TINTO
More informationWednesday 25 June Poster Session 9: BPH 1 Chairmen: M. Speakman and D. Rosario
Wednesday 25 June 14.30 15.30 Poster Session 9: BPH 1 Chairmen: M. Speakman and D. Rosario P080 Unreliable residual volume measurement after increased water load diuresis G. ALIVIZATOS, A. SKOLARIKOS,
More informationDate: 23 June Context and policy issues:
Title: Basiliximab for Immunosuppression During a Calcineurin Inhibitor Holiday in Renal Transplant Patients with Acute Renal Dysfunction: Guidelines for Use and a Clinical and Cost-Effectiveness Review
More informationDATE: 09 December 2009 CONTEXT AND POLICY ISSUES:
TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY
More informationWhat is Benign Prostatic Hyperplasia (BPH)?
What is Benign Prostatic Hyperplasia (BPH)? Benign prostatic hyperplasia (BPH) is an enlarged prostate. The prostate goes through two main growth periods as a man ages. The first occurs early in puberty,
More informationEvidence based urology in practice: heterogeneity in a systematic review meta-analysis. Health Services Research Unit, University of Aberdeen, UK
Version 6, 12/10/2009 Evidence based urology in practice: heterogeneity in a systematic review meta-analysis Mari Imamura 1, Jonathan Cook 2, Sara MacLennan 1, James N Dow 1 and Philipp Dahm 3 for the
More informationManagement of Voiding Problems in Older Men. Dr. John Fenn Consultant, QEH 10 th October, 2005
Management of Voiding Problems in Older Men Dr. John Fenn Consultant, QEH 10 th October, 2005 Voiding Problems Poor stream Hesitancy Straining Incomplete emptying Intermittent micturition Terminal dribbling
More informationEAU GUIDELINES ON NON- NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION
EAU GUIDELINES ON NON- NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION (Limited text update March 2016) S. Gravas (Chair), T. Bach, A. Bachmann, M. Drake, M. Gacci, C. Gratzke, S. Madersbacher,
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablation, of prostate, holmium laser, 485 495 African prune tree (Pygeum africanum), 454 455 Alfuzosin, 445 446 Alpha-adrenergic agonists,
More informationEFFICACY OF LASER SURGERY FOR BENIGN PROSTATIC HYPERPLASIA TREATMENT
EFFICACY OF LASER SURGERY FOR BENIGN PROSTATIC HYPERPLASIA TREATMENT Hasmeinda Medical faculty of Universitas Muhammadiyah Surakarta ABSTRACT Benign prostatic hyperplasia (BPH) is the most important cases
More informationCan men with prostates sized 80 ml or larger be managed conservatively?
Original Article - Lower Urinary Tract Dysfunction Investig Clin Urol 2017;58:359-364. pissn 2466-0493 eissn 2466-054X Can men with prostates sized 80 ml or larger be managed conservatively? Alvin Lee,
More informationEfficacy and safety of photoselective vaporization of the prostate in patients with prostatic obstruction induced by advanced prostate cancer
Asian Journal of Surgery (2011) 34, 135e139 Available online at www.sciencedirect.com journal homepage: www.e-asjsur.com ORIGINAL ARTICLE Efficacy and safety of photoselective vaporization of the prostate
More informationTITLE: Mattresses for Chronic Back or Neck Pain: A Review of the Clinical Effectiveness and Guidelines
TITLE: Mattresses for Chronic Back or Neck Pain: A Review of the Clinical Effectiveness and Guidelines DATE: 14 May 2014 CONTEXT AND POLICY ISSUES Persistent back pain is a common presentation in primary
More informationTITLE: Critical Incident Stress Debriefing for First Responders: A Review of the Clinical Benefit and Harm
TITLE: Critical Incident Stress Debriefing for First Responders: A Review of the Clinical Benefit and Harm DATE: 12 February 2010 CONTEXT AND POLICY ISSUES: Critical incident stress debriefing (CISD) is
More informationAPPENDIX CLINICAL INPUT RESPONSES
CLINICAL INPUT RESPONSES AUA: American Urological Association; UCSF Med Ctr: University of California San Francisco Medical Center; PUL: prostatic urethral lift. * Indicates that information on conflicts
More informationThe One Year Outcome after KTP Laser Vaporization of the Prostate According to the Calculated Vaporized Volume
J Korean Med Sci 9; 24: 1187-91 ISSN 111-8934 DOI: 1.3346/jkms.9.24.6.1187 Copyright The Korean Academy of Medical Sciences The One Year Outcome after KTP Laser Vaporization of the Prostate According to
More informationBenign enlargement of prostate (BEP), which is. Early Experiences with HoLEP. Original Article ABSTRACT INTRODUCTION. Bhandari BB*
Original Article Early Experiences with HoLEP Bhandari BB* * Consultant Urologist, Shree Birendra Army Hospital, Norvic International Hospital, Alka Hospital ABSTRACT introduction: Holmium Laser Enucleation
More informationManaging urinary morbidity after brachytherapy. Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester
Managing urinary morbidity after brachytherapy Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester Themes Can we predict urinary morbidity? Prevention of urinary morbidity
More information